Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer

Jingwei Li 1,†, Peiyi Li 2,†, Jun Shao 1, Shufan Liang 1, Yuntian Wan 3, Qiran Zhang 1, Changshu Li 1, Yalun Li 1,* and Chengdi Wang 1,*

1 Department of Respiratory and Critical Care Medicine, Med-X Center for Manufacturing, Frontiers Science Center for Disease-Related Molecular Network, West China Medical School/West China Hospital, Sichuan University, Chengdu 610041, China
2 Department of Anesthesiology, West China Medical School/West China Hospital, Sichuan University, Chengdu 610041, China
3 West China Medical School/West China Hospital, Sichuan University, Chengdu 610041, China
* Correspondence: liyalun@wchscu.cn (Y.L.); chengdi_wang@scu.edu.cn (C.W.)
† These authors contributed equally to this work.

Abstract: Lung cancer accounts for the majority of malignancy-related mortalities worldwide. The introduction of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of lung cancer. Nevertheless, TKI resistance impedes therapeutic efficacy and its underlying mechanisms remain unclear. This review summarizes the potential mechanisms of noncoding RNAs (ncRNAs) in EGFR TKI-resistant lung cancer and their clinical applications. Moreover, we highlight the bottlenecks that urgently need to be addressed to promote the clinical application of ncRNAs.

Keywords: EGFR-TKI resistance; ncRNAs; lung cancer; mechanism

1. Introduction

Lung cancer, the foremost malignancy in terms of mortality rates, can be divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [1,2]. NSCLC, accounting for approximately 85% of lung cancers, is mainly composed of lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD) and large cell lung cancer [2]. Over the last few decades, the rapid development of therapeutic regimens such as targeted therapy has immensely improved the prognosis of NSCLC, but the overall survival (OS) remains disappointing due to delayed diagnosis and the development of drug resistance, particularly to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) [3,4]. EGFR mutations are one of the most common targetable aberrations that facilitate the progression of malignancies [5]. The advent of EGFR-TKIs has been confirmed to prolong the OS of NSCLC patients. However, almost all patients with EGFR mutations invariably
acquire EGFR TKI resistance despite the initial encouraging response [6,7]. Although the mechanisms of resistance to EGFR TKIs have been identified as target-dependent mutations and alternative pathway activation [6,7], their underlying mechanisms are still unclear.

Noncoding RNAs, mainly including microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), show extensive tissue-restricted and cancerspecific expression patterns, which are strongly involved in tumor evolution and the development of drug resistance [8,9]. In the field of EGFR TKI-resistant lung cancer, emerging evidence has verified that dysregulated ncRNAs play an indispensable pathophysiological role by modulating crucial signaling pathways such as PI3K/AKT/mTOR, Ras/Raf/MEK/ERK, JAK/STAT and epithelial-mesenchymal transition (EMT) processes to affect resistance to EGFR TKIs [8,10]. Therefore, ncRNAs show potential as prognostic, predictive and therapeutic biomarkers for EGFR TKI-resistant lung cancer.

This review scientifically summarizes the present knowledge regarding the biogenesis and biological functions of ncRNAs, including the formation of dysregulated ncRNAs in EGFR TKI-resistant lung cancer. In addition, ncRNAs involved in the mechanisms of EGFR TKI resistance and their clinical applications are described in detail. Eventually, the bottlenecks that urgently need to be addressed to enhance the translation of ncRNA basic research to clinical practice are discussed.

2. Overview of NcRNAs

For the past few decades, the protein-coding genome has been considered the main focus of medical studies. Human genome sequencing showed that only 1% of the genome had translational function and the remaining regions were initially believed to be “junk” [11,12]. Nevertheless, recent research has indicated that the noncoding portion tends to be transcribed into multiple ncRNAs, which modulate natural pathophysiological processes such as proliferation, invasion and angiogenesis to contribute to the development of diseases, including cancer [13]. On the basis of size and function, ncRNAs can be divided into miRNAs, ncRNAs, circRNAs and so on (Figure 1).

Figure 1. Biogenesis of ncRNAs. Abbreviations: AGO, argonaute; circRNA, circular RNA; ciRNA, intronic circRNA; ecircRNA, exonic circRNA; ElciRNA, exon–intron circRNA; lncRNA, long non-coding RNA; miRNA, microRNA; ncRNA, non-coding RNA; Pol II, RNA polymerase II; TRBP, TAR RNA binding protein.
2.1. Biogenesis and Role of miRNA

MiRNAs are a category of short noncoding molecules that are approximately 19 to 25 nucleotides in length and primarily function by binding complementary sequences [14]. The biogenesis of miRNA is mediated by RNA polymerase II (Pol II), which consequently forms the primary miRNA (pri-miRNA). Following the original transcription, Drosha, along with the cofactor DGC8R8, collaboratively cleaves the pri-miRNA into pre-miRNA. Then, the pre-miRNA is exported to the cytoplasm through the Exportin 5 and Ran-GTP complex and cleaved into a miRNA duplex by TAR RNA binding protein (TRBP) and the RNase III Dicer. Finally, facilitated by the Argonaute (AGO) family of proteins, miRNA duplexes are integrated into the RNA-induced silencing complex (RISC) [15]. Mature miRNAs perform biological functions mainly via the identification of the 3′ untranslated region (UTR) to mediate mRNA degradation or mRNA expression modulation [16]. In this way, miRNAs contribute to the tumorigenesis and evolution of multiple cancers, including lung cancer [17].

2.2. Biogenesis and Role of LncRNAs

Unlike miRNAs with short nucleotides, lncRNAs consist of more than 200 nucleotides [18]. Generally, protein-coding genes synthesize mature mRNA by means of 5′ capping, 3′ cleavage and polyadenylation (CPA) and splicing. In certain circumstances, loss of CPA factors, 5′-3′ exoribonuclease 2 (XRN2), or polyadenylation site mutation may lead to prolonged read-through transcript formation. Conversely, premature transcription termination (PTT) induces truncated transcriptional products. The read-through and PTT transcripts are deemed as lncRNAs [19]. Despite distinctly lower expression levels than mRNAs, lncRNAs have a much starker tissue-restricted expression pattern [20] and perform cis-regulatory and trans-acting functions or serve as a molecular scaffold of miRNAs, mRNA, DNA and proteins to participate in physiological regulation and disease pathogenesis [21].

2.3. Biogenesis and Role of CircRNA

CircRNAs have emerged as a novel class of circular molecules displaying stronger stability than other ncRNAs due to their covalently closed nature [22]. The biogenesis of circRNA generally involves back-splicing via complementary sequences or RNA-binding proteins (RBPs) and lariat-mediated circularization [23,24]. In accordance with the composition, circRNAs containing exons are considered as exonic circRNAs (ecircRNAs), exerting fundamental biological functions as miRNA sponges and protein scaffolds in the cytoplasm [25–27]. CircRNAs consisting only of introns are named intronic circRNAs (ciRNAs), and those with both exons and introns are considered exon-intron circRNAs (EIciRNAs). EIciRNAs and ciRNAs restricted to the nucleus play critical transcriptional regulatory roles [23]. In contrast to other ncRNAs, certain circRNAs containing internal ribosome entry sites (IRESs) or with N6-methyladenosine (m6A) modification possess a translational function, which mediates pathological and physiological regulation via functional proteins or peptides [24,28]. Because of their stable structure and cancer-specific expression pattern, circRNAs can be utilized as promising biomarkers for multiple cancers.

3. Dysregulated NcRNAs in EGFR TKI-Resistant Lung Cancer

In research on malignant tumors, dysregulated expression of ncRNAs is widely observed in almost all types of cancers. Nevertheless, the underlying mechanisms remain unclear. Emerging evidence has provided two major hypotheses that partly explain the dysregulation of ncRNA expression in EGFR TKI-resistant lung cancer. If the downregulation of specific ncRNAs occurs during cancer development, one explanation is that the speed of tumor cell proliferation may be faster than that of slow generation ncRNAs, resulting in a dilution effect and significant reduction in ncRNA expression [22,29]. In contrast, individual circRNAs could be upregulated in tumors, potentially resulting from host gene mutation or chromosomal rearrangements. For instance, the oncogene MYC mutation observed in multiple cancers transactivates the miR-17–92 cluster and enhances their expression [30].
Analogously, cancer-associated chromosomal rearrangements contribute to the genesis of fusion genes and subsequently result in oncogenic ncRNAs, interfering with the migration and invasion of lung cancer cells [31]. It is commonly assumed that upregulated ncRNAs have an oncologic function. Conversely, the downregulated ncRNAs potentially have a pivotal tumor-suppressive role. Beyond tumorigenesis, recent studies have investigated dysregulated ncRNAs in EGFR TKI-resistant lung cancer and partially elucidated their diverse mechanisms. To date, research has mainly focused on specific ncRNAs involved in crucial signaling pathways downstream of EGFR and parallel pathways instead of the mechanisms of ncRNA dysregulation [32–34]. Remarkably, a minority of studies have shown that EGFR mutations might lead naturally to ncRNAs [35]. MiR-21, for example, a miRNA activated by EGFR, has been proven to negatively modulate TNF expression. In this manner, miR-21 in lung cancer treated with EGFR TKIs is inversely upregulated and thus stimulates the TNF/NF-κB pathway [35], which consequently causes EGFR TKI resistance in lung cancer. Nevertheless, the current research is incapable of clearly illustrating the underlying mechanisms relating to dysregulated ncRNAs in EGFR TKI-resistant lung cancer. Further investigation focusing on transcriptional control of ncRNAs will likely provide an in-depth understanding of EGFR TKI resistance.

4. Mechanisms of NcRNAs Involved in EGFR TKI Resistance

Acquired drug resistance has long been a major hurdle hindering the therapeutic effect of EGFR TKIs [6–8]. Accumulating evidence has indicated that ncRNAs, especially circRNAs, lncRNAs and miRNAs, play a vital role in EGFR TKI-resistant lung cancer via alternative signaling pathway modulation [10,36]. Here, ncRNAs involved in essential signaling pathways downstream and parallel pathways of EGFR are discussed in detail (Figure 2).

**Figure 2.** Mechanisms of EGFR-TKI resistance mediated by ncRNAs. Several critical ncRNAs can mediate the EGFR-TKI resistance through modulating the PI3K/AKT/mTOR, Ras/Raf/MEK/ERK, JAK/STAT, NF-κB and EMT pathways. Abbreviations: EGFR, Epidermal growth factor receptor; EMT, epithelial-mesenchymal transition; IGF1R, Insulin-like growth factor 1 receptor; PTEN, phosphatase and tensin homologue; TGF-β, transforming growth factor-β.
4.1. NcRNAs Involved in the PI3K/AKT/mTOR Signaling Pathway

The PI3K/AKT/mTOR signaling pathway is a critical signaling pathway downstream of EGFR that dramatically regulates cell proliferation, metabolism and motility and brings about EGFR TKI resistance [37]. Previous studies have validated that many ncRNAs affect the activation of the PI3K/AKT/mTOR signaling pathway by directly interacting with oncoproteins, modulating regulators and targeting effectors of the PI3K/AKT/mTOR pathway upstream.

The field of EGFR TKI resistance research has identified many ncRNAs interacting with oncoproteins, which may directly relieve the trigger of downstream signaling in EGFR TKI-resistant lung cancer and thereby reduce drug sensitivity. For instance, miR-30a-5p and miR-7 functionally attenuate the activation of PI3K and AKT, respectively, hence eliminating resistance to EGFR TKIs [38,39]. Apart from miRNAs, lncRNAs such as H19 and LINC00152 regulate the phosphorylation of AKT to restore erlotinib resistance [40,41]. Furthermore, dysregulated circRNAs serve as miRNA sponges to inactivate PI3K/AKT proteins [42,43], but their mechanisms remain unclear.

Beyond the direct coaction with oncoproteins, ncRNAs are also engaged in modulating specific factors that contribute to silencing or enhancing the PI3K/AKT/mTOR signaling pathway. Among them, phosphatase and tensin homolog (PTEN), a major antagonist of PI3K, decreases this pathway to a great extent [44]. Previous research has revealed that miR-21 silences the expression of PTEN and reinforces the PI3K/Akt pathway, resulting in acquired resistance to gefitinib [45]. In contrast, circ-PLCD1 enhances PTEN expression by binding to miR-375 and miR-1179 [46]. In addition, other modulators, including ENO1 and AGO1, lead to dysregulation of the PI3K/AKT/mTOR signaling pathway [2,33,47,48], which promotes or restricts resistance to EGFR TKIs.

In addition to interactions with oncoproteins and the regulators of the pathway, many ncRNAs contribute to EGFR TKI resistance in patients by modulating alternative signaling pathways, such as the hepatocyte growth factor (HGF) receptor and insulin-like growth factor 1 receptor (IGF1R). The hepatocyte growth factor (HGF) receptor, also known as MET, has been shown to be activated by miR-205/ERRFI1 and LINC01510. Thus, the PI3K/AKT pathway is enhanced, causing resistance to gefitinib, afatinib, erlotinib and osimertinib [49,50]. In a similar manner, ncRNAs such as miR-223, lncRNA GAS5 and hsa_circ_0005576 regulate IGF1R expression and subsequently influence the resistance of lung cancer cells to EGFR TKIs [32,51–53].

4.2. NcRNAs Involved in the Ras/Raf/MEK/ERK Signaling Pathway

The Ras/Raf/MEK/ERK signaling pathway, a well-researched oncogenic pathway, is responsible for the tumorigenesis and evolution of multiple malignancies [54] and has also been validated to be an indispensable mechanism of EGFR TKI resistance [55]. As a downstream pathway of EGFR, the Ras/Raf/MEK/ERK pathway has been confirmed to be modulated by various ncRNAs in recent years.

The majority of ncRNAs exert their biological function by influencing the activity of oncoproteins or regulatory factors of the pathway. MiR-345, for instance, directly acts on the ERK oncoprotein to eliminate the signal transduction of the Ras/Raf/MEK/ERK pathway, thereby regaining sensitivity to gefitinib [56]. Furthermore, other ncRNAs, such as miR-641, miR-630, IncRNA CASC9 and IncRNA LOC554202, maintain EGFR TKI resistance by regulating the enhancers of the pathway [57–60]. Intriguingly, LOC554202 sustains both the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways by activating miR-31 [58], indicating its potential as a promising therapeutic target for EGFR TKI-resistant lung cancer. In regard to circRNAs, C190 sponges miR-142-5p to promote EGFR/MAPK/ERK signaling [61], which may contribute to EGFR TKI resistance in lung cancer patients. However, the current evidence remains inadequate to clarify its relationship with drug resistance and experiments regarding certain EGFR TKIs are urgently needed.

The effectors of the Ras/Raf/MEK/ERK pathway also activate signaling and accordingly mediate EGFR TKI resistance. MET is one of the best-known effectors that not only
stimulates the PI3K/AKT/mTOR pathway but also facilitates the Ras/Raf/MEK/ERK pathway [62]. By directly targeting MET, miRNAs such as miR-1-3p and miR-206 attenuate gefitinib resistance by inactivating the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways [63]. In contrast, IncRNA LINCO1510 promotes MET expression to maintain EGFR TKI resistance [50]. Moreover, emerging research has indicated that circBFAR functionally promotes the MET pathway by sponging miR-34b-5p [64], which can be hypothesized to cause EGFR TKI resistance. However, insufficient experimental validation of EGFR TKI-resistant NSCLC cells or tissues obscures the mechanisms of circRNAs in MET-related drug resistance.

4.3. *ncRNAs Involved in the JAK/STAT and NF-κB Signaling Pathways*

Relying on corresponding ligands and receptors, the JAK/STAT signaling pathway exerts specific biological functions, including limited proliferation, apoptosis and even EGFR TKI resistance [65]. Many ncRNAs are involved in silencing or activating JAK/STAT signaling via interconnection with oncoproteins or upstream regulators. As exemplified by circ-E-Cad and IncRNA UCA1, some ncRNAs directly target the JAK/STAT pathway to mediate EGFR TKI resistance [66,67]. However, the current research is more focused on the upstream modulators of the JAK/STAT signaling pathway. For instance, miRNAs, including miR-19b and miR-206, indirectly modulate the JAK/STAT pathway via critical upstream signal control and consequently affect resistance to EGFR TKI [34,68]. Remarkably, miR-19b interacts with PP2A and BIM to simultaneously promote the phosphorylation of AKT, ERK and STAT [34], indicating its potential as a promising therapeutic target for affecting multiple pathways of EGFR TKI-resistant lung cancer. Similarly, IncRNA LINCO1116 attenuates the expression of IFI44, a critical upstream regulator of IFN/STAT1 signaling, to expedite gefitinib resistance [69].

Nuclear factor-κB (NF-κB) has long been known as an inducible transcription factor participating in cellular life activities, especially in malignancies [70,71]. In cancer biology, NF-κB has major functions as a proliferative stimulator and apoptotic suppressor in tumor cells, which also mediates drug resistance [70]. Notably, NF-κB not only independently sustains EGFR TKI resistance but also serves as an effector downstream of the JAK/STAT signaling pathway to enhance EGFR TKI resistance [36]. ncRNAs involved in NF-κB pathway modulation are primarily examined for their ability to target upstream regulators. For example, miR-21 induces the downregulation of TNF mRNA, which may contribute to the suppression of TNF-related NF-κB activation and thus reduce EGFR TKI resistance [35]. Conversely, ciRS-7, one of the most studied circRNAs, recruits miR-7 to activate HOXB13-mediated NF-κB, which might promote EGFR TKI resistance [72]. Nevertheless, insufficient research on ncRNAs involved in the NF-κB pathway makes it difficult to clarify their relationship with EGFR TKI-resistant lung cancer and further study is urgently needed to illustrate their underlying mechanisms.

4.4. *ncRNAs Involved in EMT*

EMT is a common cellular phenomenon that crucially leads to embryogenesis and malignant evolution. During tumorigenesis, EMT induces tumor cells to increase their invasive capability and resistance to therapeutic regimens, including chemotherapy and EGFR TKIs [73]. The EMT signaling pathways are predominantly composed of transforming growth factor-β (TGFβ), WNT and NOTCH pathways [73,74]. In the context of ncRNAs, however, EMT of EGFR TKI-resistant lung cancer is mainly restricted to the TGFβ pathway, NOTCH pathway and EMT-inducing transcription factors (Figure 3).
Figure 3. NcRNAs involved in EMT. Dysregulated ncRNAs play an important role in EGFR-TKI resistance via EMT regulation. Abbreviations: APC, adenomatous polyposis coli protein; AXIN, axis inhibition protein; E-cadherin, epithelial cadherin; EMT, epithelial-mesenchymal transition; GSK3β, glycogen synthesize kinase-3β; LEF, lymphoid enhancer-binding factor; N-cadherin, neural cadherin; NOTCH, intracellular domain of the NOTCH receptor; TCF, T cell factor; TGF-β, transforming growth factor-β.

Regarding TGF-β pathway modulation, IncRNAs such as UCA1 and HCP5 can serve as activators of the TGF-β pathway to sustain EGFR TKI resistance [75,76]. Beyond the TGF-β pathway, IncRNA SNHG15, a crucial molecule downstream of the NOTCH pathway, recruits miR-451 to enhance MDR-1 expression and thus facilitate gefitinib resistance [77]. Moreover, many ncRNAs can reinforce EGFR TKI resistance via EMT-inducing transcription factors. For example, miR-200c could affect the expression of zinc finger E-box binding 1 (ZEB1), a critical transcription factor, to sustain the transition to the mesenchymal cell state and hence induce EGFR TKI resistance [78]. Although the molecular mechanisms of ncRNAs involved in EMT described above have been elucidated, many ncRNAs associated with EGFR TKI-resistant lung cancer are merely correlated with several markers of EMT. Previous research has shown that dysregulation of circRNA CCDC66 correlates with aberrant expression of EMT markers involved in EGFR TKI resistance, such as epithelial cadherin (E-cadherin) and neural cadherin (N-cadherin), hypothesizing that these ncRNAs enhance EGFR TKI resistance via the EMT process [79]. However, due to insufficient evidence, the underlying mechanisms are still unclear.

Since EMT is a reversible process, actively intervening in EMT-related heterotypic signals or de-inducing the expression of EMT-inducing transcription factors can convert mesenchymal cells back to an epithelial state [73], which is known as mesenchymal-epithelial transition (MET). Thus, the MET process may reverse the state of EGFR TKI resistance [80]. Consistent with this hypothesis, miR-625-3p targets AXL to alleviate TGF-β-induced EMT, which consequently contributes to gefitinib resistance [81]. Furthermore, miR-506-3p suppresses SHH signaling to upregulate E-cadherin expression and downregulate vimentin expression to resensitize erlotinib-resistant cells [82]. Likewise, overexpression of the IncRNA HOTAIR was found to induce the MET process by stabilizing E-cadherin, as well as de-inducing vimentin and N-cadherin, resulting in resensitization of EGFR TKI-
resistant NSCLC cells and a better prognosis of patients [83], demonstrating its potential as a prognostic biomarker and therapeutic target for EGFR TKI-resistant lung cancer.

4.5. NcRNAs Involved in Other Mechanisms

The cooperative interaction between FGF2-fibroblast growth factor receptor (FGFR1) and EGFR in activating the PI3K/AKT/mTOR, Ras/Raf/MEK/ERK and JAK/STAT signaling pathways has been proven [84]. Accordingly, FGFR1 is generally regarded as another alternative pathway mediating EGFR TKI resistance [6,7]. In terms of ncRNAs, miR-16 targets MEK1, a downstream mediator of FGFR-1, to attenuate ERK expression and restrain the oncogenic capacity [85], which may subsequently suppress EGFR TKI resistance. Apart from FGFR-1/MEK/ERK pathway modulation, miR-214-3p inhibits FGFR1 expression to inactivate the MAPK/AKT pathway [86]. Conversely, overexpression of IncRNA PVT1 was found to functionally sponge miR-551b to upregulate FGFR1, hence promoting the proliferation and metastasis of NSCLC cells [87]. Therefore, IncRNA PVT1 shows potential as a therapeutic target for EGFR TKI-resistant NSCLC. Nonetheless, current studies of ncRNAs involved in the FGFR1 pathway predominantly focus on general NSCLC cells instead of EGFR TKI-resistant NSCLC cells and further research is urgent to illustrate the mechanisms of FGFR1-inducing EGFR TKI resistance mediated by ncRNAs.

SCLC transformation has always been a rare mechanism of acquired resistance to first-, second- and third-generation EGFR TKIs [6,7]. Multicenter research indicated that approximately 3% to 10% of EGFR-mutant NSCLC patients undergo SCLC transformation characterized by TP53 and Rb1 mutations [88]. A recent study utilized TKI-resistant profiles to establish the miRNA regulatory network and select hsa-miR-495-3p, hsa-miR-24-3p, hsa-miR-181a-5p and hsa-miR-125a-3p, which potentially participate in SCLC transformation [89]. This discovery indicates that ncRNAs might shed light on the mechanisms of SCLC transformation and an in-depth study dissecting the expression of ncRNAs at the single-cell level would promote the development of treatment concerning SCLC transformation-related EGFR TKI resistance in the future.

5. Clinical Implications of NcRNAs in EGFR-Mutant Lung Cancer

Dysregulated ncRNAs are characterized by cancer-specific and tissue-restricted expression patterns. Moreover, accumulating evidence has demonstrated that aberrant expression of individual ncRNAs dramatically correlates with TNM stage, treatment response and even prognosis of EGFR TKI-resistant lung cancer, highlighting their potential as prognostic, predictive and therapeutic biomarkers [33,90–92]. Here, the clinical implications of ncRNAs in EGFR-mutant lung cancer are listed with examples to offer a useful reference for clinical decision-making (Table 1).

5.1. NcRNAs as Prognostic Biomarkers

An increasing number of ncRNAs have been confirmed to have immense potential as prognostic biomarkers to promote medical resource allocation. For ncRNAs conferring better prognosis of EGFR-mutant NSCLC, earlier multicenter research on 319 EGFR-TKI-treated patients found that miR-608 rs4919510 and miR-4513 rs2168518 contributed to prolonged progression-free survival (PFS) with hazard ratios (HRs) of 0.63 and 0.46, respectively (p < 0.01) [93]. Consistent with the survival results, the miRNAs notably enhanced gefitinib sensitivity in H1299 and PC9 cells in vitro [93]. Analogously, overexpression of IncRNA H19 denotes an extended PFS (p = 0.021) in EGFR-mutated patients under EGFR-TKI treatment. Mechanistically, H19 contributes to erlotinib sensitivity by hindering AKT phosphorylation, resulting in survival improvement [40]. Beyond PFS prediction, some researchers are dedicated to exploring the relationship between overall survival (OS) and ncRNA expression. Loss of heterozygosity (LOH) of microRNA-128b in EGFR-mutant patients resulted in an improved OS of 23.4 versus 10.5 months [94]. In contrast, upregulated hsa_circ_0004015 alleviates the inhibition of miR-1183 to promote gefitinib resistance, which correlates with worse OS (p < 0.05), invasion (p = 0.031) and TNM stage
However, although overexpression of lncRNA SOX2-OT is significantly associated with metastasis and a lower response to EGFR-TKI treatment, no significant difference in OS was observed [96].

5.2. NcRNAs as Predictive Biomarkers

Through promotion of EGFR-TKI resistance and treatment response prediction, ncRNAs are valuable in noninvasive selection of optimal therapeutic regimens without extra toxicities. Considering the emerging preclinical evidence that ncRNAs regulate the efficacy of EGFR TKIs in vitro, ncRNA expression levels in specimens have been explored in accumulating studies to predict resistance to EGFR TKIs [97,98]. For instance, the expression of lncRNA CCAT1 was found to be upregulated in gefitinib-resistant patients compared with gefitinib-sensitive patients ($p = 0.001$) [97]. Beyond the prediction of EGFR-TKI resistance, upregulated LINC00460 in tumor specimens was correlated with worse PFS and OS ($p = 0.046$ and 0.014, respectively) [98]. Mechanistically, LINC00460 could serve as a miR-149-5p sponge to enhance IL-6 expression and thus facilitate EMT [98]. Remarkably, large amounts of ncRNAs are secreted in the form of exosomes, which makes it possible to noninvasively detect them in plasma or serum. MiR-7, the best-studied miRNA, is positively associated with gefitinib sensitivity in serum exosomes of EGFR-mutant LUAD patients ($p < 0.0001$) [99]. In contrast, miR-27a, miR-21 and miR-218 have been verified to be significantly overexpressed in the plasma of EGFR TKI-resistant NSCLC patients compared with sensitive patients ($p = 0.009$, 0.004 and 0.041, respectively) [100]. Interestingly, previous research constructed a united model containing four plasma miRNAs with significantly aberrant expression to achieve an area under the curve (AUC) of 0.869 in predicting EGFR-TKI resistance, which is better than that of any single miRNA [101]. This instructive example indicates that comprehensively utilizing multidimensional information such as ncRNAs and clinical data may attain a promising predictive performance for the treatment response of EGFR TKIs.

Other researchers have also studied the possible correlation between dynamic variations in ncRNAs in the process of TKI treatment to monitor acquired EGFR TKI resistance. Clinical investigation of miR-184 and miR-3913-5p in serum presented AUCs of 0.736 and 0.759, respectively, in acquired osimertinib-resistant NSCLC patients with exon 21 L858R [102]. In addition, the expression of miR-3913-5p was dramatically upregulated in osimertinib-resistant patients with the T790M mutation ($p = 0.013$) [102]. Other than miRNAs, exosomal circRNA_102481 is significantly upregulated in serum after the onset of EGFR TKI resistance ($p = 0.025$), demonstrating its potential as a predictive biomarker of acquired resistance [90]. Notably, lncRNA HOTAIR showed a good performance in predicting both acquired and primary EGFR TKI resistance ($p = 0.0046$ and 0.0097, respectively) [83]. The evidence above supports that HOTAIR has the ability to simultaneously monitor multiple means of EGFR-TKI resistance.

5.3. NcRNAs as Therapeutic Targets

Given that many ncRNAs participate in the modulation of EGFR TKI resistance via multiple signaling pathways, ncRNAs potentially serve as therapeutic targets or agents for EGFR TKI-resistant lung cancer [28,33,61,91,103–112].

For ncRNAs in promoting EGFR TKI resistance, loss-of-function treatment is hypothesized to have promising curative effects. Oncogenic miRNAs can be attenuated by antagoniRs. MiR-147b, for instance, has been verified to repress pseudohypoxia and the TCA cycle pathway to mediate osimertinib resistance. Pretreating osimertinib-resistant cells with antagoniR of miR-147b markedly reversed EGFR TKI resistance, indicating the therapeutic role of miR-147b [104]. With regard to lncRNAs and circRNAs, rational usage of novel techniques, including RNA interference (RNAi) and CRISPR/Cas13 systems, also show promising therapeutic effects. RNAi includes interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs), which are commonly applied to trigger gene silencing and cancer therapy [113]. By this means, overexpressed IncRNA APCDD1L-AS1 and BLACAT1
were knocked down by siRNA and shRNA, which subsequently reinstated the sensitivity to icotinib and afatinib, respectively [108,109]. Nevertheless, major challenges such as off-target effects, unsatisfactory specificity and cytotoxicity hinder their clinical application [113]. To address this issue, researchers have developed CRISPR/Cas13 systems with higher specificity and efficiency than RNAi to precisely edit ncRNAs [22]. A more recent study utilized CRISPR/Cas13a to facilitate the cleavage of circRNA C190 and further restrain the expression of EGFR-MAPK-ERK signaling, which efficiently reversed EGFR TKI resistance [61].

For ncRNAs that induce sensitivity to EGFR TKIs, establishing adenoviral/lentiviral vectors and lipid/polymer nanoparticles might enhance their expression and achieve excellent therapeutic effects. MiR-483-3p has been proven to repress the FAK/Erk pathway by targeting integrin beta3 to weaken EGFR TKI resistance. In EGFR TKI-resistant tumor models, forced miR-483-3p expression via a lentiviral vector observably stimulated gefitinib sensitivity, showing its potential as a therapeutic agent [91]. In the field of IncRNAs, increasing RHPN1-AS1 expression via a lentiviral vector resensitized gefitinib-resistant NSCLC cells in a similar manner. Mechanistically, RHPN1-AS1 alleviates TNFSF12 suppression by sponging miR-299-3p to relieve resistance to EGFR TKIs [110]. Nonetheless, gain-of-function therapy by means of constructing viral vectors inevitably generates substantial additional products that might lead to unpredictable adverse events in patients [22]. Notably, certain ncRNAs exert translational functions to modulate EGFR TKI resistance. CircASK1, for example, encodes the ASK1-272.a protein to compete with ASK1 and thus attenuate ASK1 phosphorylation mediated by Akt1, which activates gefitinib sensitivity [111]. Therefore, ncRNAs encoding tumor-suppressor proteins may serve as a novel therapeutic regimen for EGFR TKI-resistant lung cancer.

Table 1. Main prognostic, predictive and therapeutic biomarkers in EGFR-mutant lung cancer.

| Biomarker Type       | NcRNA                  | Expression | Cancer Type     | Biological Function or Role                                                                 | Reference |
|----------------------|------------------------|------------|-----------------|---------------------------------------------------------------------------------------------|-----------|
| Prognostic biomarker | microRNA-128b          | ↓          | NSCLC (tissue)  | Suppressing EGFR expression; a microRNA-128b LOH confers better OS of EGFR-mutant patients (p = 0.02) | [94]      |
|                      | miR-608                | ↓          | LUAD (tissue)   | Enhancing gefitinib sensitivity in H1299 and PC9 cells; overexpression of miR-608 and miR-4513 indicates a better PFS (HR = 0.63 and 0.46, respectively) (p < 0.01) | [93]      |
|                      | miR-4513               | ↓          |                 | Promoting erlotinib resistance by enhancing the AKT phosphorylation; overexpression of IncRNA H19 indicates an extended PFS (p = 0.021) in EGFR-mutated patients | [40]      |
|                      | IncRNA H19             | ↓          | NSCLC (tissue)  | Alleviating the inhibition of miR-1183 to promote gefitinib resistance; overexpression of hsa_circ_0004015 indicates a worse OS (p = 0.05) | [95]      |
|                      | circ_0004015           | ↑          | NSCLC (tissue)  | Promoting gefitinib sensitivity by targeting YAP; upregulation of miR-7 significantly correlates with gefitinib sensitivity (p < 0.0001) | [99]      |
| Predictive biomarker | miR-7                  | ↓          | NSCLC (serum)   | Promoting osimertinib resistance; patients with EGFR exon 21 L858R: AUC = 0.736 (miR-184) and 0.759 (miR-3913-5p) | [102]     |
|                      | miR-184                | ↑          | NSCLC (serum)   | Promoting gefitinib resistance; AUC = 0.86 (model including these miRNAs)                  | [101]     |
|                      | miR-3913-5p            | ↑          |                 |                                              |           |
|                      | miR-195, miR-122,      | ↑          | NSCLC (tissue & plasma) | Promoting gefitinib resistance; AUC = 0.869 (model including these miRNAs) |           |
|                      | miR-125, miR-21,       | ↑          |                 |                                              |           |
|                      | miR-25                 | ↑          |                 |                                              |           |
Table 1. Cont.

| Biomarker Type | NcRNA          | Expression | Cancer Type     | Biological Function or Role                                                                 | Reference |
|----------------|----------------|------------|-----------------|---------------------------------------------------------------------------------------------|-----------|
| lncRNA CCAT1   | ↑ NSCLC (tissue) | Promoting gefitinib resistance by sponging miR-218; upregulation of CCAT1 significantly correlates with gefitinib resistance (p < 0.001) | [97] |
| lncRNA HOTAIR  | ↓ NSCLC (tissue) | Promoting EGFR-TKI sensitivity by modulating EMT; downregulation of HOTAIR significantly correlates with EGFR TKI resistance (p = 0.0046, acquired resistance; p = 0.0097, primary resistance) | [83] |
| circRNA_102481| ↑ NSCLC (serum)  | Promoting EGFR TKI resistance via the microRNA-30a-5p/ROR1 axis; upregulation of circRNA_102481 significantly correlates with EGFR TKI resistance (p = 0.025) | [90] |
| miR-147b       | ↑ NSCLC (tissue) | Therapy target of miR-147b-related TCA cycle dysfunction | [104] |
| miR-150        | ↓ LUAD (tissue)  | Therapy target of the miR-150/NOTCH3/COL1A1 pathway | [103] |
| miR-483-3p     | ↓ NSCLC (cell line) | Therapy target for inhibiting integrin beta3 and thus repressing the FAK/Erk pathway | [91] |
| miR-30a-5p     | ↓ NSCLC (cell line) | Therapy target for inhibiting the PI3K/ AKT pathway | [112] |
| lncRNA APCDD1L-AS1| ↑ LUAD (cell line) | Therapy target for the miR-1322/miR-1972/miR-324-3p/SIRT5 pathway | [108] |
| lncRNA BLACAT1 | ↑ NSCLC (cell line) | Therapy target for regulating the STAT3 signaling pathway | [109] |
| lncRNA RHPN1-AS1| ↓ NSCLC (tissue) | Therapy target for inhibiting the miR-299-3p/TNFSF12 pathway | [110] |
| circRNA C190   | ↑ NSCLC (tissue)  | Therapy target for the EGFR/MAPK/ERK pathway | [61] |
| circASK1       | ↓ LUAD (tissue)   | Therapy target for activating the ASK1/JNK/p38 pathway | [111] |

The “↑” for upregulation and the “↓” for downregulation. Abbreviations: Area under the curve (AUC); Epidermal growth factor receptor (EGFR); Epithelial-mesenchymal transition (EMT); Hazard ratio (HR); Loss of heterozygosity (LOH); Lung adenocarcinoma (LUAD); Non-small cell lung cancer (NSCLC); Overall survival (OS).

6. Conclusions and Future Challenges

Over the last few decades, ncRNAs have been deemed nonfunctional coproducts of protein-coding RNAs, even though they constitute the overwhelming majority of RNAs [11,12]. The advent of RNA-sequencing and analytical technologies has strongly enhanced the exploration of ncRNA biological functions and pathophysiological roles. On this account, ncRNAs are pyramidally utilized to illustrate the tumorigenesis and progression of malignancies, creating the conditions for in-depth research on the mechanisms of EGFR TKI-resistant lung cancer [10,36]. Emerging evidence has also shown that certain ncRNAs play an indispensable role in the regulation of critical signal pathways inducing EGFR TKI resistance, including PI3K/AKT/mTOR, Ras/Raf/MEK/ERK, JAK/STAT and EMT [38,58,61,68,77].

Although research on ncRNAs has strongly increased our understanding of the underlying mechanisms of EGFR TKI resistance, most studies are limited to target-independent pathways. Consequently, the role of ncRNAs in the molecular network of EGFR TKI-resistant mutations remains unclear. In practice, a few ncRNAs derived from drug-resistant-mutated lung cancer cells have been found to facilitate EGFR TKI resistance [99,114]. There-
fore, further exploration of the mechanisms of ncRNAs in patients with EGFR TKI-resistant mutations would theoretically contribute to the comprehensive understanding of the development of EGFR TKI resistance. Despite the ambiguity regarding the mechanisms of EGFR TKI resistance, ncRNAs have long been expected to be promising biomarkers and therapeutic targets [40,61,83,94,97]. Nevertheless, no ncRNAs have truly satisfied the clinical demands and have been put into application. Several major hindrances are discussed briefly below.

The dysregulation of ncRNAs has cumulatively been affirmed to have excellent predictive and prognostic performance, but most studies are based on dozens of cases, making the results unreliable [40,90,101,102]. Hence, further investigation with a large sample size and well-designed validation cohorts is prospectively needed to identify biomarkers satisfying clinical needs. Furthermore, repression or enhancement of functional ncRNAs has been used to affect the natural progression of lung cancer and reverse EGFR TKI resistance in vivo and in vitro [61,104,106,107], indicating their therapeutic value. Nevertheless, the inescapable off-target effects and undesirable viral DNA integration in current technologies such as RNAi, CRISPR/Cas systems and adenoviral/lentiviral vectors are worrisome [10,22]. Ultimately, the particularity of ncRNA structure constitutes an impediment for practitioners. The leading concern for miRNAs and lncRNAs is their unstable nature and accordingly, these molecules are easily degraded and difficult to detect [12,115]. With regard to circRNAs, although they possess a covalently closed structure with high stability, their current profiling techniques are complicated and costly [22], leading to an insurmountable obstacle for clinical application. All things considered, the aforesaid challenges need to be overcome to expedite their translation from basic research to clinical practice.

In summary, ncRNAs show substantial translational prospects. A future study adopting a rational trial design and advanced technologies to explore the ncRNAs involved in EGFR TKI-resistant lung cancer would overcome barriers that hinder mechanistic investigation and clinical application.

**Author Contributions:** Conceptualization, C.W. and Y.L.; Writing—original manuscript, J.L. and P.L.; Writing—review and editing, J.L., P.L., J.S., S.L., Y.W., Q.Z., C.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by National Natural Science Foundation of China (82100119), the Science and Technology Project of Sichuan (grant 2020YFG0473, 2020YFS0572), Chinese Postdoctoral Science Foundation (2021M692309, 2022T150451), Postdoctoral Interdisciplinary Innovation Fund and Postdoctoral Program of Sichuan University (2021SCU12018) and Postdoctoral Program of West China Hospital, Sichuan University (2020HXBH084).

**Conflicts of Interest:** All authors declare that there is no conflict of interest.

**References**

1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. *CA Cancer J. Clin.* **2022**, *72*, 7–33. [CrossRef] [PubMed]
2. Hua, Q.; Wang, D.; Zhao, L.; Hong, Z.; Ni, K.; Shi, Y.; Liu, Z.; Mi, B. AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC. *Cancer Cell Int.* **2021**, *21*, 525. [CrossRef] [PubMed]
3. Kumagai, S.; Koyama, S.; Nishikawa, H. Antitumour immunity regulated by aberrant ERBB family signalling. *Nat. Rev. Cancer* **2021**, *21*, 181–197. [CrossRef] [PubMed]
4. Ettinger, D.S.; Wood, D.E.; Aisner, D.L.; Akerley, W.; Bauman, J.R.; Bharat, A.; Bruno, D.S.; Chang, J.Y.; Chirieac, L.R.; D’Amico, T.A.; et al. NCCN guidelines insights: Non-small cell lung cancer, version 2.2021. *J. Natl. Compr. Cancer Netw.* **2021**, *19*, 254–266. [CrossRef] [PubMed]
5. Hu, C.; Leche, C.A., 2nd; Kiyatkin, A.; Yu, Z.; Stayrook, S.E.; Ferguson, K.M.; Lemmon, M.A. Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias. *Nature 2022*, *602*, 518–522. [CrossRef] [PubMed]
6. Tan, C.S.; Kumarakulasinghe, N.B.; Huang, Y.Q.; Ang, Y.L.E.; Choo, J.R.; Goh, B.C.; Soo, R.A. Third generation EGFR TKIs: Current data and future directions. *Mol. Cancer* **2018**, *17*, 29. [CrossRef] [PubMed]
7. Westover, D.; Zugazagoitia, J.; Cho, B.C.; Lovly, C.M.; Paz-Ares, L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. *Ann. Oncol.* **2018**, *29*, 110–119. [CrossRef] [PubMed]
8. Uribe, M.L.; Marrocco, I.; Yarden, Y. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. *Cancers* **2021**, *13*, 2748. [CrossRef]
9. Zhou, X.; Hu, S.; Zhang, Y.; Du, G.; Li, Y. The mechanism by which noncoding RNAs regulate muscle wasting in cancer cachexia. *Precis Clin. Med.* 2021, 4, 136–147. [CrossRef]

10. Leonetti, A.; Assaraf, Y.G.; Veitsisita, P.D.; El Hassouni, B.; Tiseo, M.; Giovannetti, E. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions. *Drug Resist. Updat.* 2019, 42, 1–11. [CrossRef]

11. Ponting, C.P.; Oliver, P.L.; Reik, W. Evolution and functions of long noncoding RNAs. *Cell* 2009, 136, 629–641. [CrossRef] [PubMed]

12. Slack, F.J., Chinnaiyan, A.M. The role of non-coding RNAs in oncology. *Cell* 2019, 179, 1033–1055. [CrossRef] [PubMed]

13. Yi, Y.C.; Chen, X.Y.; Zhang, J.; Zhu, J.S. Novel insights into the interplay between m(6)A modification and noncoding RNAs in cancer. *Mol. Cancer* 2020, 19, 121. [CrossRef] [PubMed]

14. Lu, T.X.; Rothenberg, M.E. MicroRNA. *J. Allergy Clin. Immunol.* 2018, 141, 1202–1207. [CrossRef] [PubMed]

15. Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nat. Rev. Drug Discov.* 2017, 16, 203–222. [CrossRef]

16. Hill, M.; Tran, N. Global miRNA to miRNA interactions: Impacts for miR-21. *Trends Cell Biol.* 2021, 31, 3–5. [CrossRef]

17. Li, B.; Zhu, L.; Lu, C.; Wang, C.; Wang, H.; Jin, H.; Ma, X.; Cheng, Z.; Yu, C.; Wang, S.; et al. CircNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BP3s and activating anti-tumor immunity. *Nat. Commun.* 2021, 12, 295. [CrossRef]

18. Kopp, F.; Mendell, J.T. Functional classification and experimental dissection of long noncoding RNAs. *Nat. Rev. Mol. Cell. Biol.* 2019, 20, 1033–1055. [CrossRef] [PubMed]

19. Nojima, T.; Proudfoot, N.J. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics. *Cell* 2017, 178, 106–115. [CrossRef]

20. Bridges, M.C.; Daulagala, A.C.; Kourtidis, A. LNCcation: lncRNA localization and function. *Nat. Rev. Mol. Cell. Biol.* 2020, 21, 475–490. [CrossRef]

21. Tan, Y.T.; Lin, J.F.; Li, T.; Li, J.J.; Xu, R.H.; Ju, H.Q. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. *Cancer Commun.* 2021, 41, 109–120. [CrossRef] [PubMed]

22. Kristensen, L.S.; Jakobsen, T.; Hager, H.; Kjems, J. The emerging roles of circRNAs in cancer and oncology. *Nat. Rev. Clin. Oncol.* 2022, 19, 188–206. [CrossRef] [PubMed]

23. Wang, C.; Tan, S.; Li, J.; Liu, W.R.; Peng, Y.; Li, W. CircRNAs in lung cancer—biogenesis, function and clinical implication. *Cancer Lett.* 2020, 492, 106–115. [CrossRef] [PubMed]

24. Li, J.; Zhang, Q.; Jiang, D.; Shao, J.; Li, W.; Wang, C. CircRNAs in lung cancer—role and clinical application. *Cancer Commun.* 2022, 544, 215810. [CrossRef]

25. Chen, L.L. The expanding regulatory mechanisms and cellular functions of circular RNAs. *Nat. Rev. Mol. Cell. Biol.* 2020, 21, 467–475. [CrossRef]

26. Wang, C.; Liu, W.R.; Tan, S.; Zhou, J.K.; Xu, X.; Ming, Y.; Cheng, J.; Li, J.; Zeng, Z.; Zuo, Y.; et al. Characterization of distinct circular RNA signatures in solid tumors. *Mol. Cancer* 2022, 21, 63. [CrossRef]

27. Wang, C.; Tan, S.; Liu, W.R.; Lei, Q.; Qiao, W.; Wu, Y.; Liu, X.; Cheng, W.; Wei, Y.Q.; Peng, Y.; et al. RNA-Seq profiling of circular RNA in human lung adenocarcinoma and squamous cell carcinoma. *Mol. Cancer* 2019, 18, 134. [CrossRef]

28. Vo, J.N.; Cieslik, M.; Zhang, Y.; Shukla, S.; Xiao, L.; Zhang, Y.; Wu, Y.M.; Dhanaekaran, S.M.; Engelke, C.G.; Cao, X.; et al. The landscape of circular RNA in cancer. *Cancer* 2017, 176, 869–881.e13. [CrossRef]

29. Zhang, Y.; Xue, W.; Li, X.; Zhang, J.; Chen, S.; Zhang, J.L.; Yang, L.; Chen, L.L. The biogenesis of nascent circular RNAs. *Cell Rep.* 2016, 15, 611–624. [CrossRef]

30. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. *Nat. Rev. Genet.* 2009, 10, 704–714. [CrossRef]

31. Wu, K.; Liao, X.; Gong, Y.; He, J.; Zhou, J.K.; Tan, S.; Pu, W.; Huang, C.; Wei, Y.Q.; Peng, Y. Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer. *Mol. Cancer* 2019, 18, 98. [CrossRef] [PubMed]

32. Liu, S.; Jiang, S.; Xiao, P.; Li, X.; Chen, Y.; Tang, H.; Chai, Y.; Liu, Y.; Zhu, Z.; Xie, Q.; et al. Hsa_circ_005576 promotes osimertinib resistance through the miR-21-5p/IGFIR axis in lung adenocarcinoma cells. *Cancer Sci.* 2022, 113, 79–90. [CrossRef] [PubMed]

33. Li, Y.; Shen, Y.; Xie, M.; Wang, B.; Wang, T.; Zeng, J.; Hua, H.; Yu, J.; Yang, M. LncRNAs LCETRL3 and LCETRL4 at chromosome 4q12 diminish EGFR-TKIs efficiency in NSCLC through stabilizing TDP43 and ELF2S1. *Signal Transduct. Target. Ther.* 2022, 7, 30. [CrossRef]

34. Baumgartner, U.; Berger, F.; Hashemi Gheinani, A.; Burgener, S.S.; Monastyrskaya, K.; Vassella, E. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer. *Mol. Cancer* 2018, 17, 44. [CrossRef] [PubMed]

35. Geng, K.; Guo, G.; Gerber, D.E.; Gao, B.; Peyton, M.; Huang, C.; Minna, J.D.; Hatanpaa, K.J.; Kernstine, K.; Cai, L.; et al. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. *J. Clin. Investig.* 2018, 128, 2500–2518. [CrossRef]

36. Hassanein, S.S.; Ibrahim, S.A.; Abdel-Mawood, A.L. Cell behavior of non-small cell lung cancer is at EGFR and microRNAs hands. *Int. J. Mol. Sci.* 2021, 22, 2496. [CrossRef] [PubMed]

37. Alzahrani, A.S. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. *Semin. Cancer Biol.* 2019, 59, 125–132. [CrossRef]
38. Meng, F.; Wang, F.; Wang, L.; Wong, S.C.; Cho, W.C.; Chan, L.W. MiR-30a-5p overexpression may overcome EGFR-inhibitor resistance through regulating PI3K/AKT signaling pathway in non-small cell lung cancer cell lines. *Front. Genet.* 2016, 7, 197. [CrossRef]

39. Webster, R.J.; Giles, K.M.; Price, K.J.; Zhang, P.M.; Mattick, J.S.; Leedman, P.J. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. *J. Biol. Chem.* 2009, 284, 5731–5741. [CrossRef]

40. Chen, C.; Liu, W.R.; Zhang, B.; Zhang, L.M.; Li, C.G.; Liu, C.; Zhang, H.; Huo, Y.S.; Ma, Y.C.; Tian, P.F.; et al. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and activation of AKT in EGFR-mutant lung cancers. *Cancer Lett.* 2020, 486, 58–70. [CrossRef]

41. Zhang, Y.; Xiang, C.; Wang, Y.; Duan, Y.; Liu, C.; Jin, Y.; Zhang, Y. LncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway. *Biomed. Pharmacother.* 2017, 94, 644–651. [CrossRef] [PubMed]

42. Du, A.; Li, S.; Zhou, Y.; Disoma, C.; Liao, Y.; Zhang, Y.; Chen, Z.; Yang, Q.; Liu, P.; Liu, S.; et al. M6A-mediated upregulation of circular RNAs promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. *Mol. Cancer* 2022, 21, 109. [CrossRef] [PubMed]

43. Liu, Y.; Wang, X.; Bi, L.; Huo, H.; Yan, S.; Cui, Y.; Cui, Y.; Gu, R.; Jia, D.; Zhang, S.; et al. Identification of differentially expressed circular RNAs as miRNA sponges in lung adenocarcinoma. *J. Oncol.* 2021, 2021, 5193913. [CrossRef]

44. Haddadi, N.; Lin, Y.; Travis, G.; Simpson, A.M.; Nassif, N.T.; McGowan, E.M. PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy. *Mol. Cancer* 2018, 17, 37. [CrossRef] [PubMed]

45. Li, B.; Ren, S.; Li, X.; Wang, Y.; Garfield, D.; Zhou, S.; Chen, X.; Su, C.; Chen, M.; Kuang, P.; et al. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. *Lung Cancer* 2014, 83, 146–153. [CrossRef] [PubMed]

46. Si, J.; Jin, J.; Sai, J.; Liu, X.; Luo, X.; Fu, Z.; Wang, J. Circular RNA circ-PLCD1 functions as a tumor suppressor in non-small cell lung cancer by inactivation of AKT signaling pathway. *Hum. Cell* 2022, 35, 924–935. [CrossRef]

47. Zhou, G.; Zhang, F.; Guo, Y.; Huang, J.; Xie, Y.; Yue, S.; Chen, M.; Jiang, H.; Li, M. MiR-200c enhances sensitivity of drug-resistant non-small lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibits cell migration via targeting ZEB1. *Biomed. Pharmacother.* 2017, 85, 113–119. [CrossRef] [PubMed]

48. Wang, X.; Li, R.; Feng, L.; Wang, J.; Qi, W.; Yu, Z. Hsa_circ_0001666 promotes non-small cell lung cancer migration and invasion through miR-1184/miR-548I/AGO1 axis. *Mol. Ther. Oncolytics* 2022, 24, 597–611. [CrossRef]

49. Migliore, C.; Morando, E.; Ghiso, E.; Anastasi, S.; Leoni, V.P.; Apicella, M.; Cora, D.; Sapino, A.; Pietrantonio, F.; De Braud, F.; et al. MiR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. *EMBO Mol. Med.* 2018, 10, e8746. [CrossRef] [PubMed]

50. Pal, A.S.; Agredo, A.; Lanman, N.A.; Son, J.; Sohal, I.S.; Bains, M.; Li, C.; Clingerman, J.; Gates, K.; Kasinski, A.L. Loss of KMT5C promotes EGFR inhibitor resistance in NSCLC via LINC01510-mediated upregulation of MET. *Cancer Res.* 2022, 82, 1534–1547. [CrossRef]

51. Hua, J.; Wang, X.; Ma, L.; Li, J.; Cao, G.; Zhang, S.; Lin, W. CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGFIR/AKT axis. *Mol. Cancer* 2022, 21, 123. [CrossRef] [PubMed]

52. Dong, S.; Qu, X.; Li, W.; Zhong, X.; Li, P.; Yang, S.; Chen, X.; Shao, M.; Zhang, L. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. *J. Hematol. Oncol.* 2015, 8, 43. [CrossRef] [PubMed]

53. Han, J.; Zhao, F.; Zhang, J.; Zhu, H.; Ma, H.; Li, X.; Peng, L.; Sun, J.; Chen, Z. MiR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. *Int. J. Oncol.* 2016, 48, 1855–1867. [CrossRef] [PubMed]

54. Samatar, A.A.; Poulikakos, P.I. Targeting RAS-ERK signalling in cancer: Promises and challenges. *Nat. Rev. Drug Discov.* 2014, 13, 928–942. [CrossRef]

55. Fernandes Neto, J.M.; Nadal, E.; Bosdriesez, E.; Ooft, S.N.; Farre, L.; McLean, C.; Klarenbeek, S.; Jurgens, A.; Hagen, H.; Wang, L.; et al. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. *Nat. Commun.* 2020, 11, 3157. [CrossRef]

56. Lu, M.; Liu, B.; Xiong, H.; Wu, F.; Hu, C.; Liu, P. Trans-3,5,4-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. *J. Cell Mol. Med.* 2019, 23, 2431–2441. [CrossRef]

57. Chen, Z.; Chen, Q.; Cheng, Z.; Gu, J.; Feng, W.; Lei, T.; Huang, J.; Pu, J.; Chen, X.; Wang, Z. Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1. *Cell Death Dis.* 2020, 11, 858. [CrossRef]

58. He, J.; Jin, S.; Zhang, W.; Wu, D.; Li, J.; Xu, J.; Gao, W. Long non-coding RNA LOC554202 promotes acquired gefitinib resistance in non-small cell lung cancer through upregulating miR-31 expression. *J. Cancer* 2019, 10, 6003–6013. [CrossRef]

59. Chen, J.; Cui, J.D.; Guo, X.T.; Cao, X.; Li, Q. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NFI1. *Cancer Res.* 2018, 78, 1394–1403. [CrossRef]

60. Wu, D.W.; Wang, Y.C.; Wang, L.; Chen, C.Y.; Lee, H. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. *Theranostics* 2018, 8, 1256–1269. [CrossRef]
61. Ishola, A.A.; Chien, C.S.; Yang, Y.P.; Chien, Y.; Yarmishyn, A.A.; Tsai, P.H.; Chen, J.C.; Hsu, P.K.; Luo, Y.H.; Chen, Y.M.; et al. Oncogenic circRNA C190 promotes non-small cell lung cancer via modulation of the EGFR/ERK pathway. *Cancer Res.* **2022**, *82*, 75–89. [CrossRef] [PubMed]

62. Awad, M.M.; Oxnard, G.R.; Jackman, D.M.; Savukoski, D.O.; Hall, D.; Shivdasani, P.; Heng, J.C.; Dahlberg, S.E.; Janne, P.A.; Verma, S.; et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. *J. Clin. Oncol.* **2016**, *34*, 721–730. [CrossRef] [PubMed]

63. Jiao, D.; Chen, J.; Li, Y.; Tang, X.; Wang, J.; Xu, W.; Song, J.; Li, Y.; Tao, H.; Chen, Q. MiR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. *J. Cell Mol. Med.* **2018**, *22*, 3526–3536. [CrossRef]

64. Guo, X.; Zhou, Q.; Su, D.; Luo, Y.; Fu, Z.; Huang, L.; Li, Z.; Jiang, D.; Kong, Y.; Li, Z.; et al. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis. *Mol. Cancer* **2020**, *19*, 83. [CrossRef] [PubMed]

65. Lin, X.; Farooqi, A.A. Cucurbitacin mediated regulation of deregulated oncogenic signaling cascades and non-coding RNAs in different cancers: Spotlight on JAK/STAT, Wnt/beta-catenin, mTOR, TRAIL-mediated pathways. *Semin. Cancer Biol.* **2021**, *73*, 302–309. [CrossRef] [PubMed]

66. Gao, X.; Xia, X.; Li, F.; Zhang, M.; Zhou, H.; Wu, X.; Zhong, J.; Zhao, Z.; Zhao, K.; Liu, D.; et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling. *Nat. Cell Biol.* **2021**, *23*, 278–291. [CrossRef] [PubMed]

67. Zhang, B.; Wang, H.; Wang, Q.; Xu, J.; Jiang, P.; Li, W. Knockout of IncRNA UCA1 inhibits drug resistance to gefitinib via targeting STAT3 signaling in NSCLC. *Minerva Med.* **2019**, *110*, 273–275. [CrossRef]

68. Yang, Y.; Meng, W.; Chang, H.; Han, Z.; Xu, X.; Zhang, T. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells. *J. Cell. Mol. Med.* **2019**, *23*, 7331–7341. [CrossRef]

69. Wang, H.; Lu, B.; Ren, S.; Wu, F.; Wang, X.; Yan, C.; Wang, Z. Long noncoding RNA LINC01116 contributes to gefitinib resistance in non-small cell lung cancer through regulating IFI44. *Mol. Ther. Nucleic Acids* **2020**, *19*, 218–227. [CrossRef]

70. Zhang, Q.; Linardic, M.J.; Baltimore, D. 30 years of NF-kappaB: A blossoming of relevance to human pathobiology. *Cell 2017*, *168*, 37–57. [CrossRef]

71. Perkins, N.D. The diverse and complex roles of NF-kappaB subunits in cancer. *Nat. Rev. Cancer* **2012**, *12*, 121–132. [CrossRef] [PubMed]

72. Li, R.C.; Ke, S.; Meng, F.K.; Lu, J.; Zou, X.J.; He, Z.G.; Wang, W.F.; Fang, M.H. CiRS-7 promotes growth and metastasis of esophageal squamous cell carcinoma via regulation of miR-7/HOXB13. *Cell Death Dis.* **2019**, *8*, 838. [CrossRef] [PubMed]

73. Dongre, A.; Weinberg, R.A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. *Nat. Rev. Mol. Cell Biol.* **2019**, *20*, 69–84. [CrossRef] [PubMed]

74. Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. *Nat. Rev. Clin. Oncol.* **2017**, *14*, 611–629. [CrossRef] [PubMed]

75. Chen, X.; Wang, Z.; Tong, F.; Dong, X.; Wu, G.; Zhang, R. IncRNA UCA1 promotes gefitinib resistance as a ceRNA to target FOSL2 by sponging miR-143 in non-small lung cancer. *Mol. Theraeutics* **2020**, *19*, 643–653. [CrossRef]

76. Jiang, L.; Wang, R.; Fang, L.; Ge, X.; Chen, L.; Zhou, M.; Zhou, Y.; Xiong, W.; Hu, Y.; Tang, X.; et al. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis. *Theranostics* **2019**, *9*, 2460–2474. [CrossRef]

77. Huang, J.; Pan, B.; Xia, G.; Zhu, J.; Li, C.; Feng, J. IncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1. *Cell Death Dis.* **2020**, *11*, 525. [CrossRef]

78. Liu, C.C.; Wu, C.Y.; Tseng, J.T.; Hung, C.H.; Wu, S.Y.; Huang, Y.T.; Chang, W.Y.; Su, P.L.; Su, W.C. Extracellular vesicle miR-200c enhances gefitinib sensitivity in heterogeneous EGFR-Mutant NSCLC. *Biomedicines* **2021**, *9*, 243. [CrossRef]

79. Joseph, N.A.; Chiou, S.H.; Lung, Z.; Yang, C.L.; Lin, T.Y.; Chang, H.W.; Sun, H.S.; Gupta, S.K.; Yen, L.; Wang, S.D.; et al. The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR expression and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. *J. Hematol. Oncol.* **2018**, *11*, 74. [CrossRef]

80. Li, K.; Zhu, X.; Yuan, C. Inhibition of miR-185-3p Confers erlotinib resistance through upregulation of PFKL/MET in lung cancers. *Front. Cell Dev. Biol.* **2021**, *9*, 677860. [CrossRef]

81. Du, W.; Sun, L.; Liu, T.; Zhu, J.; Zeng, Y.; Zhang, Y.; Wang, X.; Liu, Z.; Huang, J.A. The miR6253p/AXL axis induces nonT790M acquired resistance to EGFRTKI via activation of the TGFbeta/Smad pathway and EMT in EGFRmutant nonsmall cell lung cancer. *Oncol. Rep.* **2020**, *44*, 185–195. [CrossRef] [PubMed]

82. Haque, I.; Kawsar, H.I.; Motes, H.; Sharma, M.; Banerjee, S.; Banerjee, S.K.; Godwin, A.K.; Huang, C.H. Downregulation of miR-506-3p facilitates EGFR-TKI resistance through induction of sonic hedgehog signaling in non-small cell lung cancer cell lines. *Int. J. Mol. Sci.* **2020**, *21*, 9307. [CrossRef] [PubMed]

83. Wang, Q.; Li, X.; Ren, S.; Su, C.; Li, C.; Li, W.; Yu, J.; Cheng, N.; Zhou, C. HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. *Lung Cancer* **2020**, *147*, 99–105. [CrossRef]

84. Quintanar-Villalonga, A.; Molina-Pinelo, S.; Ciraquichi, C.; Ojeda-Marquez, L.; Marragal, A.; Suarez, R.; Conde, E.; Ponce-Aix, S.; Enguita, A.B.; Carnero, A.; et al. FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy. *J. Thorac. Oncol.* **2019**, *14*, 641–655. [CrossRef] [PubMed]
Cancers 2022, 14, 4423

85. Andriani, F.; Majorini, M.T.; Mano, M.; Landoni, E.; Miceli, R.; Facchinetti, F.; Mensah, M.; Fontanella, E.; Dugo, M.; Giacca, M.; et al. MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR1- and MEK1-dependent manner. J. Hematol. Oncol. 2018, 11, 45. [CrossRef] [PubMed]

86. Yang, Y.; Li, Z.; Yuan, H.; J.; W.; Wang, K.; Lu, T.; Yu, Y.; Zeng, Q.; Li, F.; Xia, W.; et al. Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. Oncogenesis 2019, 8, 50. [CrossRef]

87. Mao, W.; Wang, K.; Xu, B.; Zhang, H.; Sun, S.; Hu, Q.; Zhang, L.; Liu, C.; Chen, S.; Wu, J.; et al. CiRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Mol. Cancer 2021, 20, 142. [CrossRef]

88. Marcoux, N.; Gettinger, S.N.; O’Kane, G.; Arbour, K.C.; Neal, J.W.; Husain, H.; Evans, T.L.; Brahmer, J.R.; Muzikansky, A.; Bonomi, P.D.; et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes. J. Clin. Oncol. 2019, 37, 278–285. [CrossRef]

89. Wang, Z.; Zhang, L.; Xu, W.; Li, J.; Liu, Y.; Zeng, X.; Zhong, M.; Zhu, Y. The multi-omics analysis of key genes regulating EGFR-TKI resistance, immune infiltration, SCLC transformation in EGFR-mutant NSCLC. J. Inflamm. Res. 2022, 15, 649–667. [CrossRef]

90. Yang, Y.; Li, Z.; Yuan, H.; J.; W.; Wang, K.; Lu, T.; Yu, Y.; Zeng, Q.; Li, F.; Xia, W.; et al. Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. Oncogenesis 2019, 8, 50. [CrossRef]

91. Yue, J.; Lv, D.; Wang, C.; Li, L.; Zhao, Q.; Chen, H.; Xu, L.; Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3. Oncogene 2018, 37, 4300–4312. [CrossRef] [PubMed]

92. Park, K.S.; Moon, Y.W.; Raffeld, M.; Lee, D.H.; Wang, Y.; Giaccone, G. High cryptpo-1 and low miR-205 expression levels as prognostic markers in early-stage non-small cell lung cancer. Lung Cancer 2018, 116, 38–45. [CrossRef] [PubMed]

93. Zhang, N.; Li, Y.; Zheng, Y.; Zhang, L.; Pan, Y.; Yu, J.; Yang, M. MiR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs. Lab. Investig. 2019, 99, 568–576. [CrossRef] [PubMed]

94. Weiss, G.J.; Bemis, L.T.; Nakajima, E.; Sugita, M.; Birks, D.K.; Robinson, W.A.; Varella-Garcia, M.; Bunn, P.A., Jr.; Haney, J.; Helfrich, B.A.; et al. EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 2008, 19, 1053–1059. [CrossRef]

95. Zhou, Y.; Zheng, X.; Xu, B.; Chen, L.; Wang, Q.; Deng, H.; Jiang, J. Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of small-cell lung cancer by miR-1183/PDPK1 signaling pathway. Biochem. Biophys. Res. Commun. 2019, 508, 527–535. [CrossRef]

96. Herrera-Solorio, A.M.; Peralta-Arrieta, I.; Armas Lopez, L.; Hernandez-Cigala, N.; Mendoza Millá, C.; Ortiz Quintero, B.; Catalan Cardenas, R.; Pineda Villlages, P.; Rodriguez Villanueva, E.; Trejo Iriarte, C.G.; et al. LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases. Mol. Oncol. 2021, 15, 1110–1129. [CrossRef]

97. Jin, X.; Liu, X.; Zhang, Z.; Guan, Y. LncRNA CCAT1 acts as a microRNA-218 sponge to increase gefitinib resistance in NSCLC by targeting HOXA1. Mol. Ther. Nucleic Acids 2020, 19, 1266–1275. [CrossRef]

98. Nakano, Y.; Isobe, K.; Kobayashi, H.; Caburaki, K.; Ishihiki, T.; Sakamoto, S.; Takai, Y.; Tochigi, N.; Mikami, T.; Iyoda, A.; et al. Clinical importance of long noncoding RNA LINC00460 expression in EGFRmutant lung adenocarcinoma. Int. J. Oncol. 2020, 56, 243–257. [CrossRef]

99. Chen, R.; Qian, Z.; Xu, X.; Zhang, C.; Niu, Y.; Wang, Z.; Sun, J.; Zhang, X.; Yu, Y. Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small cell lung cancer. Pharmcol. Res. 2021, 165, 105442. [CrossRef]

100. Wang, S.; Su, X.; Bai, H.; Zhao, J.; Duan, J.; An, T.; Zhao, M.; Wang, Z.; Wu, M.; Li, Z.; et al. Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. J. Hematol. Oncol. 2015, 8, 127. [CrossRef]

101. Zhao, Q.; Cao, J.; Wu, Y.C.; Liu, X.; Han, J.; Huang, X.C.; Jiang, L.H.; Hou, X.X.; Mao, W.M.; Ling, Z.Q. Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. Am. J. Cancer Res. 2015, 5, 1692–1705. [CrossRef]

102. Li, X.; Chen, C.; Wang, Z.; Liu, J.; Sun, W.; Shen, K.; Lv, Y.; Zou, S.; Zhan, P.; Lv, T.; et al. Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell cancer. Cancer Cell Int. 2021, 21, 428. [CrossRef] [PubMed]

103. Zhang, Y.; Chen, B.; Wang, Y.; Zhao, Q.; Wu, W.; Zhang, P.; Miao, L.; Sun, S. NOTCH3 overexpression and posttranscriptional regulation by miR-150 were associated with EGFR-TKI resistance in lung adenocarcinoma. Cancer Res. 2021, 87, 751–761. [CrossRef] [PubMed]

104. Zhao, Q.; Cao, J.; Wu, Y.C.; Liu, X.; Han, J.; Huang, X.C.; Jiang, L.H.; Hou, X.X.; Mao, W.M.; Ling, Z.Q. Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. Am. J. Cancer Res. 2015, 5, 1692–1705. [CrossRef]

105. Li, X.; Chen, C.; Wang, Z.; Liu, J.; Sun, W.; Shen, K.; Lv, Y.; Zou, S.; Zhan, P.; Lv, T.; et al. Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell cancer. Cancer Cell Int. 2021, 21, 428. [CrossRef] [PubMed]

106. Zhang, Y.; Chen, B.; Wang, Y.; Zhao, Q.; Wu, W.; Zhang, P.; Miao, L.; Sun, S. NOTCH3 overexpression and posttranscriptional regulation by miR-150 were associated with EGFR-TKI resistance in lung adenocarcinoma. Cancer Res. 2021, 87, 751–761. [CrossRef] [PubMed]

107. Zhang, Y.; Chen, B.; Wang, Y.; Zhao, Q.; Wu, W.; Zhang, P.; Miao, L.; Sun, S. NOTCH3 overexpression and posttranscriptional regulation by miR-150 were associated with EGFR-TKI resistance in lung adenocarcinoma. Cancer Res. 2021, 87, 751–761. [CrossRef] [PubMed]

108. Chen, X.; Mao, R.; Su, W.; Yang, X.; Geng, Q.; Guo, C.; Wang, Z.; Wang, J.; Kresty, L.A.; Beer, D.G.; et al. Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PKRKA/AMPKalpha signaling in STK11 mutant lung cancer. Autophagy 2020, 16, 659–671. [CrossRef] [PubMed]

109. Jiao, D.; Jiang, C.; Zhu, L.; Zheng, J.; Liu, X.; Liu, X.; Chen, J.; Tang, X.; Chen, Q. MiR-1-133a and miR-206/133b clusters overcome HGF induced gefitinib resistance in non-small cell lung cancers with EGFR sensitive mutations. J. Drug Target. 2021, 29, 1111–1117. [CrossRef] [PubMed]
107. Bach, D.H.; Luu, T.T.; Kim, D.; An, Y.J.; Park, S.; Park, H.J.; Lee, S.K. BMP4 upregulation is associated with acquired drug resistance and fatty acid metabolism in EGFR-mutant non-small-cell lung cancer cells. *Mol. Ther. Nucleic Acids* 2018, 12, 817–828. [CrossRef]

108. Wu, J.; Zheng, C.; Wang, Y.; Yang, Z.; Li, C.; Fang, W.; Jin, Y.; Hou, K.; Cheng, Y.; Qi, J.; et al. LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma. *Biomark. Res.* 2021, 9, 9. [CrossRef]

109. Shu, D.; Xu, Y.; Chen, W. Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling. *J. Drug Target.* 2020, 28, 300–306. [CrossRef]

110. Li, X.; Zhang, X.; Yang, C.; Cui, S.; Shen, Q.; Xu, S. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. *Cell Cycle* 2018, 17, 1772–1783. [CrossRef]

111. Wang, T.; Liu, Z.; She, Y.; Deng, J.; Zhong, Y.; Zhao, M.; Li, S.; Xie, D.; Sun, X.; Hu, X.; et al. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. *Cancer Lett.* 2021, 520, 321–331. [CrossRef] [PubMed]

112. Wang, F.; Meng, F.; Wong, S.C.C.; Cho, W.C.S.; Yang, S.; Chan, L.W.C. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. *Ther. Adv. Respir. Dis.* 2020, 14, 175346620915156. [CrossRef] [PubMed]

113. Setten, R.L.; Rossi, J.J.; Han, S.P. The current state and future directions of RNAi-based therapeutics. *Nat. Rev. Drug Discov.* 2019, 18, 421–446. [CrossRef] [PubMed]

114. Liu, X.; Jiang, T.; Li, X.; Zhao, C.; Li, J.; Zhou, F.; Zhang, L.; Zhao, S.; Jia, Y.; Shi, J.; et al. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway. *J. Cell. Mol. Med.* 2020, 24, 1529–1540. [CrossRef] [PubMed]

115. Anastasiadou, E.; Jacob, L.S.; Slack, F.J. Non-coding RNA networks in cancer. *Nat. Rev. Cancer* 2018, 18, 5–18. [CrossRef]